Nociceptin vs Ziconotide
Head-to-head comparison of Nociceptin (Nociceptin/orphanin FQ) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Nociceptin | Ziconotide |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Nociceptin/orphanin FQ | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | 1881.1 Da | 2639.1 Da |
| Half-Life | ~minutes | approximately 4.5 hours |
| Amino Acids | 17 | 25 |
| Typical Dose | no approved human dose|research-only | 0.5-19.2 mcg/day |
| Route | intrathecal|intranasal | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 44 | 500 |
| Research Status | Pre-clinical | Approved |
Nociceptin Benefits
- ✓allodynia reduction
- ✓central pain modulation
- ✓neuropathic pain research
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Nociceptin Dosing
no established human dose|research-only dosing varies
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Nociceptin Side Effects
- ⚠sedation
- ⚠dysphoria
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
Nociceptin
Nociceptin is a major pain-pathway peptide in the spinal cord, brainstem, and trigeminal system. Its relevance to migraine and neuropathic pain is mainly preclinical, where receptor-selective tools are being explored.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.